These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 25963062)

  • 1. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
    Farhangian ME; Feldman SR
    Am J Clin Dermatol; 2015 Aug; 16(4):285-294. PubMed ID: 25963062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidrug antibodies in psoriasis: a systematic review.
    Hsu L; Snodgrass BT; Armstrong AW
    Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
    Wald JM; Klufas DM; Strober BE
    J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate and other chemotherapeutic agents used to treat psoriasis.
    Jeffes EW; Weinstein GD
    Dermatol Clin; 1995 Oct; 13(4):875-90. PubMed ID: 8785891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate and psoriasis in the era of new biologic agents.
    Saporito FC; Menter MA
    J Am Acad Dermatol; 2004 Feb; 50(2):301-9. PubMed ID: 14726893
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of methotrexate in patients with psoriasis.
    Kuhn A; Ruland V; Patsinakidis N; Luger TA
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S138-44. PubMed ID: 21044448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of psoriasis. Part 2. Systemic therapies.
    Lebwohl M; Ali S
    J Am Acad Dermatol; 2001 Nov; 45(5):649-61; quiz 662-4. PubMed ID: 11606913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.
    Busard CI; Menting SP; van Bezooijen JS; van den Reek JM; Hutten BA; Prens EP; de Jong EM; van Doorn MB; Spuls PI
    Trials; 2017 Feb; 18(1):52. PubMed ID: 28148280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines on the use of methotrexate in psoriasis].
    Carretero G; Puig L; Dehesa L; Carrascosa JM; Ribera M; Sánchez-Regaña M; Daudén E; Vidal D; Alsina M; Muñoz-Santos C; López-Estebaranz JL; Notario J; Ferrandiz C; Vanaclocha F; García-Bustinduy M; Taberner R; Belinchón I; Sánchez-Carazo J; Moreno JC;
    Actas Dermosifiliogr; 2010 Sep; 101(7):600-13. PubMed ID: 20858386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.
    Bissonnette R; Ho V; Langley RG
    J Cutan Med Surg; 2009; 13 Suppl 2():S67-76. PubMed ID: 19799829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.